## Financial events: agenda 2012

<table>
<thead>
<tr>
<th>Event</th>
<th>Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q4 Full Year Sales 2011</td>
<td>25 January 2012</td>
</tr>
<tr>
<td>Annual Accounts 2011</td>
<td>7 March 2012</td>
</tr>
<tr>
<td>Q1 Sales 2012</td>
<td>2 May 2012</td>
</tr>
<tr>
<td>Q2 Sales 2012</td>
<td>25 July 2012</td>
</tr>
<tr>
<td>Half Year Results 2012</td>
<td>31 August 2012</td>
</tr>
<tr>
<td>Q3 Sales 2012</td>
<td>6 November 2012</td>
</tr>
</tbody>
</table>

Financial year ended 31 December

*Subject to modification
**Press releases are distributed after the financial markets closure

---

**About STENTYS:**
Based in Princeton, N.J., and Paris, Stentys has developed a new generation of stents to treat acute myocardial infarction (AMI). Founded by Jacques Séguin, M.D., Ph.D., and Gonzague Issenmann, Stentys received the CE mark for its flagship products in 2010. Its self-apposing stents adapt to the anatomic changes of the arteries in the post-infarction phase and thus prevent the malapposition problems associated with conventional stents. Stentys has commenced its marketing activities in several European countries. **More information on www.stentys.com.**

**Contacts:**

**Stentys**
Stanislas Piot  
CFO  
Tel.: +33 (0)1 44 53 99 42  
stan.p@stentys.com

**NewCap.**
Investor relations & Financial Communications  
Axelle Vuillermet / Pierre Laurent  
Tel.: +33 (0)1 44 71 94 94  
stentys@newcap.fr

STENTYS is listed on NYSE Euronext Paris  
**ISIN: FR0010949404 – STNT**